Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
August 2025
The pharmacovigilance automation market is rapidly advancing on a global scale, with expectations of accumulating hundreds of millions in revenue between 2025 and 2034. Market forecasts suggest robust development fueled by increased investments, innovation, and rising demand across various industries.
The pharmacovigilance automation market is expanding rapidly due to increasingly stringent safety regulations and growing adverse effects of drug reactions. Growing adoption of AI-based tools like NLP and machine learning is speeding up the automation in adverse event signal, intake, and triage identification in a short period and affordable price. North America is dominated by huge R&D investments by pharmaceutical companies and advanced healthcare IT infrastructure, while Asia Pacific is the fastest growing due to the high volume of clinical trials and strong regulatory framework.
The pharmacovigilance automation market includes the application of advanced technologies such as artificial intelligence (AI), machine learning (ML), robotic process automation (RPA), and natural language processing (NLP) to enhance the efficiency, accuracy, and scalability of drug safety monitoring and adverse event (AE) reporting. Automation helps reduce manual workloads, ensures compliance with global regulatory standards (e.g., FDA, EMA, PMDA), and improves the quality and timeliness of pharmacovigilance (PV) processes, including case intake, signal detection, risk management, and literature screening.
AI Integration in the pharmacovigilance automation is driving the growth of the market as AI-driven tools gather data from the adverse drug effect form and assess the case validity instead of the workforce. Enhanced the accuracy and quality of the data. AI-driven technology handles or manages various types of incoming data formats. It is used for the detection of ADRs. AI is useful to lower the burden and time of case processing. AI-driven pharmacovigilance offers numerous advantages over outdated methods, including enhanced drug safety through faster detection, immediate monitoring, enhanced accuracy, and scalability. It processes huge amounts of data from various sources worldwide. AI enables earlier identification of possible challenges and adverse drug reactions. Its capability to incorporate predictive analytics and personalized safety assessments ensures advanced patient results while lowering human error and expense.
For instance,
Increasing Volume of Adverse Drug Reactions
The increasing volume of adverse drug reactions is driven by higher drug consumption and the rapid development of new medications. These reactions can lead to personal injuries, hospital overcrowding, and rising healthcare costs, placing a significant burden on national health systems. Pharmacovigilance has traditionally focused on identifying adverse drug events that were previously unknown or poorly understood. It plays a crucial role in clinical research, with many centers monitoring drug safety worldwide. However, as we entered the 21st century, pharmacovigilance faced major challenges in ensuring better drug safety and monitoring. This has highlighted the need for automated systems to quickly identify and report adverse drug reactions (ADRs), thereby fueling the growth of the pharmacovigilance automation market.
Challenges of Automation in Pharmacovigilance
AI might have difficulty disambiguating terms and precisely detecting adverse events. Unstructured documents often lack complete patient information, medical histories, or treatment details essential for effective pharmacovigilance analysis. AI models processing unstructured data, such as deep learning models, can also be hard to interpret. This transparency issue can raise regulatory and compliance concerns, which in turn restrict the expansion of the pharmacovigilance automation market.
What are the Benefits of Robotic Process Automation?
Robotic Process Automation offers several privacy and security benefits. Emerging technologies enable more efficient case intake, enhanced employee productivity, quicker hypothesis-to-testing cycles, and better risk-benefit assessments. Automating pharmacovigilance allows resources to focus on monitoring and evaluating adverse drug reactions, analyzing real-world evidence, and investigating signals. This automation also reduces pharmacovigilance costs, increases precision and consistency in testing, and decreases errors, opening opportunities in the pharmacovigilance automation market.
By function, the case processing & reporting segment dominated in the pharmacovigilance automation market in 2024 with a 42% share, as it is an important activity in PV. It offers data for the investigation of adverse effects that enables to identification of novel safety concerns and to occasionally assess the profit-to-challenge ratio related to the use of a pharmaceutical product. It allows different stakeholders, like patients, healthcare professionals, and competent authorities, to exchange large amounts of security data. Case reports are significant for identifying novel safety signals by describing rare or late adverse effects that might remain unobserved in clinical trials.
On the other hand, the regulatory compliance automation segment is expected to grow at the fastest CAGR over the forecast period, 2025 to 2035, as automation in regulatory compliance confirms that medications and healthcare devices meet strict quality, safety, and efficacy standards before reaching the marketplace. Agencies such as the FDA, EMA, and WHO enforce guidelines such as GMP, GCP, and GDP in all stages of distribution and development. Observing these guidelines is vital for maintaining public trust and ensuring the success of medical companies.
By technology, the robotic process automation (RPA) segment dominated in the pharmacovigilance automation market in 2024 with a 36% share, as it enhanced operational efficiency by streamlining workflows and lowering risk, resulting in fewer delays and rework, minimizing operational expenses. Robotic process automation expertise has several privacy and security benefits. Pharmaceutical companies significantly reduce human errors and increase data accuracy, leading to better decisions. RPA in pharmacovigilance is its ability to reduce response times in adverse effect reporting.
On other hand, the natural language processing (NLP) segment is expected to grow at the fastest CAGR over the forecast period, 2025 to 2035, as it has become a significant tool in the sector of pharmacovigilance, the discipline dedicated to assessing, detecting, understanding, and avoiding adverse effects or any other medicine-related challenges. NLP allows for the efficient handling of vast amounts of unstructured data, such as patient records and social media posts, which are rich in real-world data on drug effects. NLP in pharmacovigilance helps regulatory compliance and quickens the reporting to health authorities.
By deployment mode, the cloud-based segment dominated the market in 2024, and it is expected to sustain the position during the forecast period, with a 61% share, as it provides robust security features, including data encryption, safe access protocols, and consistent backups. Cloud-based solutions are an emerging solution to help pharmacovigilance, and fundamentally constitute the delivery of computing services through the internet. This comprises storage, servers, networking, analytics, software, and intelligence. Smoother data integration is another benefit of utilising cloud-based systems in PV.
By technology, the pharmaceutical & biotechnology companies segment dominated in the pharmacovigilance automation market in 2024 with 48% share, as this companies are fundamentally the same as those of government agencies, which is to defend patients from needless harm by identifying earlier unrecognised drug complexity, explicating pre-disposing factors, refuting incorrect safety signals and enumerating challenges concerning benefit. PV is making healthcare professionals and patients aware of the contraindications, indications, doses, administration routes, and adverse effects.
On the other hand, the academic & research institutions segment is expected to grow at the fastest CAGR over the forecast period, 2025 to 2035, as it offers a platform for leading research on drug safety, enhancing patient care through informed prescribing, and improving government compliance. Such institutes collaborate with top market players, which further promotes the growth of the market.
North America dominated the pharmacovigilance automation market in 2024, with a 45% share, as the growing early adoption of automation in the healthcare sector, including pharmacovigilance, in this region, due to automated systems proficiently handling inventory management, order fulfilment, and tracking, ensuring appropriate delivery of medicines and reducing errors. North America has adverse drug reactions monitoring systems, such as the FDA Adverse Event Reporting System (FAERS), which is a database that comprises data on adverse events and medication error reports submitted to the FDA, contributing to the growth of the market.
In June 2024, the FDA’s Center for Drug Evaluation and Research (CDER) announced that it is publishing a notice in the Federal Register introducing the Emerging Drug Safety Technology Meeting (EDSTM) program. The meetings, which will be administered through CDER’s Emerging Drug Safety Technology Program (EDSTP), will provide those involved in pharmacovigilance activities (Source - Pharmtech)
In the United States, a strong presence of pharmacovilance tech providers such as Invenio, Prevnos Inc., OmniSol dot Tech, RAPAhub, and many others, these companies drive the innovation and wide adoption of automated solutions, which majorly drive the growth of the market. The growing volume of clinical trials in the United States due to the rising prevalence of chronic diseases, increasing R&D expenditure in biotechnology and pharmaceuticals, and growing demand for personalized medicine, which also needs automation, is driving the growth of the market.
Integrating AI into the Canadian healthcare system helps save money, improve efficiency, and improve patient care. AI-driven technologies help promote harmless and more productive medical care systems. Recent studies have shown that AI technology improves human abilities in terms of precision, effectiveness, and timely implementation of medical and associated administrative processes, driving the growth of the market.
Asia Pacific is estimated to host the fastest-growing market during the forecast period as the Asia Pacific region is a progressively grow as dynamic centers of scientific, technological, and commercial novelty due to rapid launch of enterprising products in the healthcare industry sectors is raises the expectations of consumers and customers, and also increasing digital technology in healthcare in APAC drives the growth of the market.
For Instance,
China's pharmacovigilance system is increasing due China's marketing authorization holders (MAHs) strengthen their pharmacovigilance abilities as the main responsible departments for drug security. Increasingly integrating advanced solutions in the whole healthcare delivery system is a vital strategy for transforming health services in China, driving the growth of the market.
India's modern healthcare transformation holds huge potential to improve healthcare efficiency and accessibility. With sustained policy support, infrastructure advancement, and public-private partnership, the country is poised to emerge as a worldwide leader in digital health, which drives the growth of the market.
Europe is expected to grow significantly in the pharmacovigilance automation market during the forecast period, as growing advanced pharmacovigilance technology in this region, such as the European Medicines Agency (EMA), launched an improved EudraVigilance system to provide changes to electronic reporting necessities. EU pharmacovigilance helps to monitor the advantages and challenges of medicines, identify emerging safety signals, which drive the growth of the market.
Germany is the largest healthcare sector and a worldwide leader in R&D, with a yearly revenue of €59.8 billion and €7.4 billion in healthcare investments. Germany’s cutting-edge regulatory framework, world-class infrastructure, and access to the EU sector make it a major investment destination for healthcare services, which contributes to the growth of the market.
The UK government is increasing funding for AI in healthcare, including drug safety automation, which drives the growth of the market. The growth of Contract Research Organisations (CROs) has been driven by enlarged investment in research and development, an increase in clinical trials, and the patent expirations of drugs, which increases the need for automation, contributing to the growth of the market.
In April 2025, Ann-Marie Orange, CIO and global head of R&D at ArisGlobal, Stated, “By integrating LifeSphere Advanced Signals, our customers are renovating pharmacovigilance by allowing earlier detection of safety challenges, accelerating decision-making, and supporting more targeted risk management strategies. By leveraging intelligent automation and real-time data insights, we’re not just enhancing regulatory compliance, we’re proactively caring for patients and building greater trust in the safety of medicines worldwide.” (Source - Pharmaceutical manufacturer)
By Functio
By Technology
By Deployment Mode
By End User
By Region
August 2025
August 2025
August 2025
August 2025